title: Global Approach to Hematologic Malignancies.
abstract: Treatment of childhood hematologic malignancies requires multidisciplinary care and reliable infrastructural support; creating a this structure in resource-poor settings remains challenging. Ideally therapy would be tailored to each region and disease. The development of research initiatives is essential. Acute lymphoblastic leukemia (ALL) and lymphomas are common in low- and middle-income countries; treatment is often resource intense but likely cost effective. Outcomes currently are worse than those reported in high-income countries. Chronic myeloid leukemia can be treated effectively with imatinib. Strategies to decrease the burden of therapy and robust palliative care programs are essential for optimal treatment of all afflicted children.
authors.affiliation: Pediatric Stem Cell Transplant, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02115, USA. Electronic address: Leslie_Lehmann@DFCI.Harvard.edu.
authors.forename: Leslie
authors.initials: L
authors.lastname: Lehmann
authors.affiliation: Department of Pediatric Oncology, 1 Fostat Street, Sayda Zainab, Cairo 11757, Egypt.
authors.forename: Alaa
authors.initials: A
authors.lastname: El-Haddad
authors.affiliation: Department of Pediatric Oncology, McMaster University, 1200 Main Street West, Hamilton, Ontario L8S 4J9, Canada.
authors.forename: Ronald D
authors.initials: RD
authors.lastname: Barr
mesh_terms: D000367:Age Factors; D003695:Delivery of Health Care; D003906:Developing Countries; D019468:Disease Management; D014943:Global Health; D017048:Health Care Costs; D019337:Hematologic Neoplasms / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D006801:Humans; D015994:Incidence; D059039:Standard of Care; D016896:Treatment Outcome
keywords: Global; Hematologic malignancies; Leukemia; Low- and middle-income countries (LMIC); Lymphoma; Pediatric